Volume 7.02 | Jan 22

Cord Blood News 7.02 January 22, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Composite Endpoint of Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation
Investigators examined a novel composite endpoint of graft-versus-host disease (GvHD)-free/relapse-free survival where events include grade III-IV acute GvHD, systemic therapy-requiring chronic GvHD, relapse, or death in the first post-hematopoietic cell transplantation year. [Blood] Abstract
Learn More: StemSpan™ Myeloid Expansion Supplement
PUBLICATIONS (Ranked by impact factor of the journal)
Enrichment of Human Hematopoietic Stem/Progenitor Cells Facilitates Transduction for Stem Cell Gene Therapy
CD34+/CD38 cells were isolated from healthy cord blood CD34+ cells by fluorescence activated cell sorting and transduced with a lentiviral vector expressing an anti-sickling form of beta-globin. In vivo studies showed engraftment of transduced CD34+/CD38 cells when transplanted in competition with 100-fold more CD34+/CD38+ cells. [Stem Cells] Abstract

Immune Reconstitution/Immunocompetence in Recipients of Kidney plus Hematopoietic Stem/Facilitating Cell Transplants
Researchers prospectively evaluated immune reconstitution and immunocompetence. Return of CD4 and CD8 T central and effector memory cell populations was rapid. T-cell receptor Excision Circle analysis showed a significant proportion of chimeric cells produced were being produced de novo. [Transplantation] Abstract

Allogeneic Stem Cell Transplantation for Refractory Acute Myeloid Leukemia: A Single Center Analysis of Long-Term Outcome
Investigators analyzed the long-term outcome of 131 consecutive patients with active acute myeloid leukemia, which was either primary refractory or unresponsive to salvage chemotherapy. [Eur J Haematol] Abstract

Onset of Ocular Graft-versus-Host Disease Symptoms after Allogeneic Hematopoietic Stem Cell Transplantation
Researchers studied the factors affecting the time to onset of ocular graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. [Cornea] Abstract

Outcomes of Peripheral Blood Stem Cell Transplantation Patients from HLA-Mismatched Unrelated Donor with Antithymocyte Globulin (ATG)-Thymoglobulin versus ATG-Fresenius: A Single-Center Study
Retrospective analysis of patients who underwent HLA-mismatched peripheral blood stem cell transplantation from unrelated donors and received pre-transplant ATG-Thymoglobulin at a total dose of 10 mg/kg or ATG-Fresenius at a total dose of 20 mg/kg was performed. [Med Oncol] Abstract

Lentiviral-Mediated Overexpression of Homeobox A4 by Human Umbilical Cord Mesenchymal Stem Cells Repairs Full-Thickness Skin Defects
The effect of homeobox A4 (HOXA4) overexpression by human umbilical cord mesenchymal stem cells (hUMSCs) on fullthickness skin repair was evaluated. Isolated hUMSCs were transfected with a lentivirus expressing HOXA4 and cultured for 21 days. [Mol Med Rep] Abstract

Human Umbilical Cord and Dental Pulp-Derived Mesenchymal Stem Cells: Biological Characteristics and Potential Roles In Vitro and In Vivo
The differentiation, survivin modified effects and molecular basis of human umbilical cord derived mesenchymal stem/stromal cells and dental pulp derived stem cells were investigated. [Mol Med Rep]
Abstract | Download Full Article

Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
Recent Advances in Primary Cutaneous T-Cell Lymphoma
There has been an incredible effort made to improve the understanding and treatment of cutaneous T-cell lymphoma. Recent findings indicate that epigenetic aberrations are integral to active disease. [Curr Opin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate Adcetris and Bristol-Myers Squibb’s immunotherapy Opdivo in two planned Phase I/II clinical trials. [Bristol-Myers Squibb] Press Release

Bellicum Pharmaceuticals Announces Successful Dosing of First Patient Cohort with BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant
Bellicum Pharmaceuticals, Inc. announced that the first cohort of patients in the BP-004 trial has completed dosing with the company’s genetically engineered donor T cells (BPX-501) after receiving a partial T depleted haplo-identical allogeneic hematopoietic stem cell transplant. [Bellicum Pharmaceuticals, Inc.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
Request your free copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cellular Therapy 2015 – 8th International Symposium on the Clinical Use of Cellular Products
March 19-20, 2015
Erlangen, Germany

NEW 2nd International Congress on Stem Cell and Cellular Therapies (ICSCCT)
October 15-18, 2015
Antalya, Turkey

Visit our events page to see a complete list of events in the cord blood community.
NEW Director (California Institute for Regenerative Medicine)

NEW Postdoctoral Researcher – Umbilical Cord Derived HSCs and MSCs (University of Crete)

Principal Investigator – Stem Cell Biology, Hematopoiesis and Hematology (Guangzhou Women and Children’s Medical Center)

PhD Studentships – Expansion of Umbilical Cord Blood Stem Cells (University College London)

Postdoctoral Position – Hematopoietic Gene Regulation and Leukemia (Boston Children’s Hospital)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Cord Tissue Processing Technician (Cord Blood Registry)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us